The available data about the mechanisms of RIG-I and MDA5 action and about their similarities and differences open up the opportunity for regulating their activity in order to improve the efficiency and safety of non-immunotherapeutic applications as well as vaccines against infectious diseases and cancer. The gene discussed is RIGI; the disease is infectious disease.